<p>Fosrolapitant/palonosetron (Ritanine^®; 瑞坦宁^®) is a fixed-dose combination of fosrolapitant, a novel neurokinin-1 (NK-1) receptor antagonist prodrug, and palonosetron, a second generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist. It is being developed by Fujian Shengdi Pharmaceutical as a preventative treatment of chemotherapy-induced nausea and vomiting. On the 29^th of May 2025, fosrolapitant/palonosetron received its first approval in China for the prevention of acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy in adults. This article summarizes the milestones in the development of fosrolapitant/palonosetron leading to this first approval in chemotherapy-induced nausea and vomiting.</p>